Navigation Links
Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
Date:11/10/2008

---------

Results of Operations

For the three months ended September 30, 2008, the Company recorded a net loss of $5,032,796 ($0.22 per common share) compared to a net loss of $4,098,978 ($0.18 per common share) for the three months ended September 30, 2007.

This increase in net loss of $933,818 or 23% is due to an increase in research and development expenses primarily resulting from an increase in clinical development costs related to ELND005 (AZD-103). The increase in net loss is also attributed to increases in general and administrative expenses and amortization expense as well as a decrease in interest income. The increase in net loss was partially offset by foreign exchange gains resulting from the Company's US dollar investments.

Research and Development

Research and development expenses increased $1,016,249 or 37% from $2,765,799 for the three months ended September 30, 2007 to $3,782,048 for the three months ended September 30, 2008. This increase was primarily the result of a significant increase in clinical development costs related to the ongoing Phase II ELND005 (AZD-103) trial. The increase was partially offset by decreases in direct clinical program expenses that related to the Company's TT-223 resulting from the reimbursement from Lilly.

General and Administrative

General and administrative expenses increased to $1,548,098 for the three months ended September 30, 2008 from $1,332,181 for the same period ended September 30, 2007. The increase of $215,917 or 16%, primarily resulted from increased stock option expense, salaries, and financial regulatory compliance costs, which were partially offset by a decreases in professional and regulatory costs as the comparative period contained increased costs associated with the NASDAQ listing of August 2007.

Interest Income, net

Interest income for the three months ended September 30, 2008 was $413,624 as compared to $596,479 for the three months ende
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Respiratory Leaders Urge Medical Community to Educate Patients Transitioning CFC to HFA Inhalers
2. Transitions Optical to Provide Free Vision Screenings at the American Diabetes Associations Feria de Salud por tu Familia(TM)
3. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
4. Schering-Plough Announces Transition of Animal Health Leadership
5. ACS Signs $27 Million Contract with Alaska to Transition Fiscal Agent Services for State Medicaid Program
6. MidSouth eHealth Alliance to Transition to Commercial Software Solution from Informatics Corporation of America
7. Transition Therapeutics Announces No Material Change
8. Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans
9. Transition Therapeutics Announces Executive Management Appointments
10. AGA Medical Announces Management Transition
11. Booth Radiology Associates Chooses IDC To Complete Its Transition To Digital Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... Dallas, Texas (PRWEB) August 23, 2014 ... deterioration of the function of the myocardium (the ... heart failure; common symptoms are dyspnea (breathlessness) and ... cardiomyopathy are often at risk of dangerous forms ... The most common form of cardiomyopathy is dilated ...
(Date:8/23/2014)... "I have heard female patients complain about making ... an inventor from Lake Stevens, Wash. "In order to ... up with this urine-collection aid." , He developed the ... from women more easily. The accessory prevents messes. It ... The invention improves sanitation and prevents the spread of ...
(Date:8/23/2014)... 2014 "Many men refuse to touch ... up getting covered in urine and spit," said an ... bathroom situations, I came up with this hygienic device." ... a man raises the toilet seat before urinating. The ... This reduces contact with dirt and germs. The accessory ...
(Date:8/23/2014)... 2014 The report “Polycarbonate Resin ... Forecasts to 2018” defines and segments the global ... the global revenue and consumption. It also identifies ... resin market with analysis of trends, opportunities, burning ... consumption and revenues are forecasted on the basis ...
(Date:8/23/2014)... 2014 GranuFlo lawsuit ( http://www.thegranuflolawsuit.com ... NaturaLyte dialysis concentrate recall continue to mount in ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... the U.S. Judicial Panel on Multidistrict Litigation (JPML) ... pending in the proceeding. In July, the Panel ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 4
... Taclonex; Company ... ST. DAVID,S, Bermuda, Nov. 9 Warner Chilcott,Limited (Nasdaq: ... 2007. Revenue in the quarter ended September 30, 2007 totaled,$226.5 million, ... of the increase in revenue were the net sales of two,products ...
... and Send ... Delegation, OAKLAND, Calif., ... have,donated $10,000 in support of RNs striking in Kentucky and West Virginia,and ... as part,of a solidarity caravan to join the action against Appalachian Regional,Healthcare ...
... BASKING RIDGE, N.J., Nov. 9 Hooper Holmes,Inc. (Amex: ... services,today announced financial results for the third quarter ended ... million compared to $60.6,million in the corresponding period of ... quarter of 2007 of $10.6 million, or $(0.16) per ...
... due to non-recurring event in 2007, net loss stable ... Canadian dollars unless otherwise noted), BELLEVILLE, ON, Nov. ... research-based, technology-driven Canadian,biopharmaceutical company, today announced financial results for ... 30, 2007. "We are also focused on the ...
... Warrant Redemption To Reduce Debt and Enhance Financial Flexibility To Fund ... ... 9 Smart Balance, Inc.,(Nasdaq: SMBL ) today announced its results ... third quarter of 2007, the Company,reported net sales of approximately $42 million ...
... Pa. and SAN DIEGO, Nov. 9 ,RS&A, Inc. ... oncology equipment sales and service, announced today that ... Oncology Systems, Inc.,(ROS), an oncology and diagnostic imaging ... US provider of oncology equipment service,and distributor of ...
Cached Medicine News:Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Nurses From Across Nation Join Solidarity Caravan in Support of Striking Kentucky RNs 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 3Health News:Hooper Holmes Announces Third Quarter 2007 Results 4Health News:Hooper Holmes Announces Third Quarter 2007 Results 5Health News:Hooper Holmes Announces Third Quarter 2007 Results 6Health News:Hooper Holmes Announces Third Quarter 2007 Results 7Health News:Bioniche Reports Fiscal 2008 First Quarter 2Health News:Bioniche Reports Fiscal 2008 First Quarter 3Health News:Bioniche Reports Fiscal 2008 First Quarter 4Health News:Bioniche Reports Fiscal 2008 First Quarter 5Health News:Bioniche Reports Fiscal 2008 First Quarter 6Health News:Bioniche Reports Fiscal 2008 First Quarter 7Health News:Bioniche Reports Fiscal 2008 First Quarter 8Health News:Bioniche Reports Fiscal 2008 First Quarter 9
(Date:8/22/2014)... N.C. , Aug. 22, 2014  Medical Science ... and thought leaders in the healthcare sector. As the ... the iPad is changing how Medical Science Liaisons (MSLs) ... MSLs are using the tablet to not only ... also to better coordinate thought leader interactions across geographies ...
(Date:8/22/2014)... , August 22, 2014 ... Markets ( http://www.researchandmarkets.com/research/x34qgv/global_laboratory ) has announced the addition ... 2014-2018"  report to their offering.  ... is an essential instrument for any modern ... precise weighing of materials. It can be ...
(Date:8/22/2014)... , August 22, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... with a sterile environment in a healthcare ... is equipped with technically advanced equipment, which ...
Breaking Medicine Technology:iPads Enhancing Medical Science Liaison Interactions with Thought Leaders, New Study Shows 2Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2
... STXS ) announced today that it intends, subject ... in a registered public offering pursuant to its existing shelf ... intends to grant the underwriters of the offering an option ... if any. Stereotaxis plans to use the proceeds ...
... Diabetes experts at a meeting convened by the U.S. ... of Health (NIH) took the next step in advancing ... forth clinical recommendations to ensure the safe and effective ... are pleased at today,s meeting there was a strong ...
Cached Medicine Technology:Stereotaxis Announces Public Offering of Common Stock 2Stereotaxis Announces Public Offering of Common Stock 3Stereotaxis Announces Public Offering of Common Stock 4JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 2JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 3JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 4
The Concept Plus also allows users to transfer large bottles, flasks and other equipment, quickly and efficiently. The front-loading interlock features class leading one touch operation and easy acce...
Providing a perfect combination of capacity, speed and innovation, the Concept 400 delivers simple sophistication and new levels of comfort and convenience....
Lose the variability of anaerobic jars and step into the 21st century with the anaerobic workstation that provides the answer to the common problems associated with anaerobic microbiology....
... Enduro is the ideal partner when ... before, during or directly after an ... adjustment and the filigreed construction, MARS ... examination, induction and operating theatre. Universal ...
Medicine Products: